INTRODUCTION

In the present day, animal care management has drastically improved compared to the situation at the end of last century. Companion animals are now living longer and so are more commonly manifesting age-related and/or pain-associated diseases of medical importance such as cancer, arthritis and metabolic disorders (Giorgi, 2012).

The most commonly used drugs in the treatment of acute and chronic canine pain belong to the class of non-steroidal anti-inflammatory drugs (NSAIDs). Nonselective or preferential NSAIDs inhibit both COX isoforms (COX-1/COX-2) to different extents. The second generation of NSAIDs (coxibs) is highly selective for the COX-2 enzyme, reducing but not eliminating the risk of some adverse effects and maintaining anti-inflammatory and analgesic actions that would alleviate inflammation and pain states. Different members of the coxib class are available for the treatment of canine OA including cimicoxib, deracoxib, firocoxib, mavacoxib and robenacoxib (Giorgi et al., 2012; Kim & Giorgi, 2013).

Osteoarthritis (OA) is a progressive condition that leads to joint inflammation, cartilage damage, pain and disability (Rychel, 2010). A number of approved NSAIDs are available for the treatment of pain associated with this chronic joint condition (Johnston et al., 2008; Kim & Giorgi, 2013; McLaughlin, 2000). The administration is usually lifelong and some of the above-mentioned drugs may produce side effects. For this reason, there is the need for new drugs effective for OA pain relief with a better safety and effectiveness profiles.

Grapiprant (Galliprant®) is an analgesic and anti-inflammatory drug. This compound is the pioneer member of the novel piprant class. It is a potent and specific antagonist of the prostaglandin E2 receptor 4 (EP4). It was approved in veterinary medicine by the FDA in 2016 for the control of pain and inflammation associated with osteoarthritis in dogs at the dose regimen of 2 mg/kg once a day by the FDA and EMA (for pain only) in 2016 and 2018, respectively. The aim of this narrative review was to report the analytical methods, pharmacokinetics, pharmacodynamics and safety of grapiprant in several animal species using the best available published scientific evidence. In conclusion, most of the analytical methods proposed for grapiprant detection are simple, reliable, sensitive and validated. The pharmacokinetics show discrepancies between animal species. The therapeutic efficacy seems more suited to chronic rather than acute pain.

KEYWORDS
analytical method, grapiprant, pharmacodynamics, pharmacokinetics, review, safety
2 | PHYSICO-CHEMICAL FEATURES

Grapiprant (C26H29N5O3S, 3-[2-(4-[2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl]phenyl)ethyl]-1-(4-methylbenzenesulfonyl)urea) is a small molecule with a molecular weight of 491.61 g/mol. It is characterized by a logP of 4.56 and a melting point >136°C. It appears as a white to off-white crystalline powder soluble in DMSO, but with a very poor water solubility (0.041 mg/L). Its molecular structure is depicted in Figure 1.

![Chemical structure of grapiprant](image)

**FIGURE 1** Chemical structure of grapiprant (1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl) sulfonylurea)

3 | ANALYTICAL METHODS

A number of analytical methods for the quantification of grapiprant in different biological matrices have been published (Baralla et al., 2018; Cox et al., 2020; De Vito et al., 2016, 2017; Heit et al., 2018; Knych et al., 2018; Łebkowska-Wierszewska et al., 2017; Nagahisa & Okumura, 2017). The devices used for the quantification of grapiprant are HPLC and LC-MS/MS. The sample clean up mainly uses liquid-liquid or solid-phase extractions and the limits of quantification range from 50 to 0.005 ng/ml. The most important details of each analytical method are reported in Table 1.

| Reference | Clean-up | Matrix | LOQ | Analytical method | Validated following FDA/EMA guideline |
|-----------|----------|--------|-----|-------------------|---------------------------------------|
| Rausch-Derra and Rhodes (2016) | NA | Feline serum | NA | NA | NA |
| De Vito et al. (2017) | Liquid-liquid extraction | Rabbit plasma | 10 ng/ml | HPLC-FL | Yes |
| Nagahisa and Okumura (2017) | Liquid-liquid extraction | Canine plasma | NA | LC/MS/MS | NA |
| Heit et al. (2018) | NA | NA | NA | LC/MS/MS | NA |
| Knych et al. (2018) | Plasma deproteinization | Horse serum | 0.005 ng/ml | LC-MS/MS | Yes |
| Solid-phase extraction | Horse urine | 0.1 ng/ml | |
| Cox et al. (2020) | Liquid-liquid extraction | Horse plasma | 50 ng/ml | HPLC-FL | Yes |
| | Horse urine | 50 ng/ml | |
| Łebkowska-Wierszewska, Barsotti, et al. (2017) | Liquid-liquid extraction | Canine plasma | 10 ng/ml | HPLC-FL | Yes |
| Rausch-Derra, Rhodes, et al. (2016) | NA | Canine serum | NA | LC/MS/MS | Yes |
| Łebkowska-Wierszewska, De Vito, et al. (2017) | Liquid-liquid extraction | Feline plasma | 1 ng/ml | HPLC-FL | Yes |
| Baralla et al. (2018) | Liquid-liquid extraction | Rabbit plasma | 5 ng/ml | LC-MS/MS | Yes |
| De Vito et al. (2016) | Liquid-liquid extraction | Canine plasma | 10 ng/ml | HPLC-FL | Yes |

Abbreviation: NA, not available.

4 | PHARMACOKINETICS

The pharmacokinetics of grapiprant have mainly been described in the canine species although a few pioneer studies have been published in cats, horses and rabbits (Table 2). Other unpublished studies (at the time of submission of this review) are ongoing in small ruminants and birds.

4.1 | Dogs

A study in a tightly controlled research environment was conducted with Beagle dogs (Nagahisa & Okumura, 2017). Grapiprant was administered to animals in accordance with the exact body weight (methyl cellulose suspension of grapiprant at 1, 3 and 10 mg/kg PO and 1 mg/kg IV). The plasma concentration of grapiprant after 1, 3 and 10 mg/kg PO administration rapidly increased with $T_{max}$ of...
| Reference                                      | n    | Species                     | Drug formulation                      | Feed status | Route of administration | Dosage schedule | Dose              | Safety data                                                                 |
|-----------------------------------------------|------|-----------------------------|---------------------------------------|-------------|-------------------------|----------------|-------------------|-----------------------------------------------------------------------------|
| Rausch-Derra and Rhodes (2016)                | 24   | Cats                        | Gelatine capsule                      | Fasted      | PO                      | Daily for 28 days | 3, 9, or 15 mg/kg | No adverse effects were detected at doses ≤15 mg/kg                         |
| De Vito et al. (2017)                         | 12   | New Zealand White rabbits   | Solution in ethanol                    | Fasted      | IV                      | Single dose    | 2 mg/kg          | NA                                                                          |
| Nagahisa and Okumura (2017)                   | 12   | Beagle dogs                 | Suspension in methylcellulose          | Fasted      | PO                      | Single dose    | 1, 3 and 10 mg/kg | No visible side effects                                                     |
|                                      |      |                             | Solution in sulfobutylether-β-cyclodextrin | IV          |                         |                | 1 mg/kg          |                                                                              |
| Heit et al. (2018)                            | 8    | Mdr1-deficient collies      | Tablet                                 | Fasted      | PO                      | Daily for 28 days | 2 mg/kg          | No visible side effects                                                     |
| Knych et al. (2018)                           | 12   | Thoroughbred horses         | Tablet suspended in water              | Fasted      | PO                      | Single dose    | 2 mg/kg          | No visible side effects                                                     |
| Cox et al. (2020)                             | 6    | Mares                       | Tablet suspended in water              | Fasted      | Via nasogastrian tube   | Single dose    | 2 mg/kg          | No visible side effects                                                     |
| Łebkowska-Wieruszewska, Barsotti, et al. (2017) | 8   | Labrador retriever dogs     | Gelatine capsule                       | Fasted      | PO                      | Single dose    | 2 mg/kg          | No visible side effects                                                     |
|                                      |      |                             | Ethanol solution                       | Fed         | PO                      |                | 2 mg/kg          |                                                                              |
|                                      |      |                             | Ethanol solution                       | Fed         | IV                      |                | 0.5 mg/kg         |                                                                              |
| Rausch-Derra, Rhodes, et al. (2016)           | 16   | Beagle dogs                 | Tablet and suspension                  | Fasted      | PO                      | Single dose    | 6 and 50 mg/kg   | No severe side effects (mild gastrointestinal signs)                         |
| Łebkowska-Wieruszewska, De Vito, et al. (2017) | 6   | European cats               | Gelatine capsule                       | Fasted      | PO                      | Single dose    | 2 mg/kg          | No visible side effects                                                     |
|                                      |      |                             | Ethanol solution                       |             | IV                      |                | 2 mg/kg          |                                                                              |
| Rausch-Derra, Huebner, et al. (2016)          | 285  | Beagle dogs with natural OA | Tablet                                 | NA          | PO                      | Daily for 28 days | 0, 2 mg/kg       | No visible side effects (drug-related adverse events were mild and transient) |
| Rausch-Derra et al. (2015)                    | 36   | Beagle dogs                 | Suspension in methylcellulose          | Fed         | PO                      | Daily for 9 months | 0, 1, 6 and 50 mg/kg | Animals remain clinically normal                                             |

Abbreviation: NA, not assessed.
0.42–0.67 h. The plasma levels of grapiprant increased in a dose-dependent manner but not in linear fashion (AUC0–24 were 1800, 7600 and 31,000 ng h/ml for 1, 3 and 10 mg/kg, respectively). This behaviour might be due to the small animal sample size of the study (3 animals for group). The serum protein binding of grapiprant was high (95%). The grapiprant t1/2λz range was relatively broad 3.7–6.1 h. Surprisingly, the absolute bioavailability values were 62%, 90% and 110% at the doses of 1, 3 and 10 mg/kg, respectively. The apparent increase in F% with increasing doses was speculated to be due to saturation of efflux pumps and/or enzymatic metabolism.

The bioavailability of grapiprant after oral administration was estimated in fasted and fed Labrador retriever dogs (Łebkowska-Wieruszewska, Barsotti, et al., 2017). The IV dose at 0.5 mg/kg, freshly dissolved in ethanol at 50 mg/mL, was administered to two animals. The plasma concentrations vs. time curves of the two dogs were almost identical. The oral dose was 2 mg/kg. This dose was prepared by micronizing the pure grapiprant powder manually in a mortar and putting the required dose into empty gelatine capsules. Animals (n = 6) received PO grapiprant after both fasting for 12 h overnight and in fed conditions. In this latter status, animals were fed one hour prior to drug administration. After oral administration of grapiprant to fed dogs, there was a delay in absorption, but this varied between dogs. The fed condition resulted in a reduced Cmax 614 vs. 1598 ng/ml and delayed Tmax (3 vs. 1 h) compared to fasting dogs. This result differs from that presented by the pharmaceutical company (Anonymous, 2016b). The t1/2z was similar to that observed in the oral fasted and IV groups. The estimated absolute bioavailability in the fed group was 66.19% while it was almost twice that in fasting animals. Despite this large difference, the decrease in concentrations of grapiprant in plasma triggered by the fed condition mostly affected Cmax but had negligible effects on the time when concentrations were greater than the theoretical canine minimal effective concentration (MEC) (Nagahisa & Okumura, 2017).

Sixteen Beagle dogs were randomized to receive single doses of either 6 or 50 mg/kg grapiprant as both suspension and tablet formulations within a cross-over design with a 15-day washout in order to evaluate its pharmacokinetics (Rausch-Derra et al., 2016). Grapiprant rapidly achieved elevated concentrations in the sera, with mean Tmax of <2 h regardless of formulation. Half-lives ranged between approximately 3 and 11 h. As expected, the higher dose resulted in substantially higher Cmax and AUC last values compared to the lower dose. However, this increase did not correlate with the dose in a linear fashion as it had in the study of Nagahisa and Okumura (2017). A likely explanation for this discrepancy is the non-linearity of clearance and volume of distribution with dose, as speculated by Łebkowska-Wieruszewska, Barsotti, et al. (2017).

### Table 3

| Study                                      | Cmax or C0 (ng/ml) | Tmax (h) | t1/2kel (h) | Cl (ml/h/kg) | Vss (ml/kg) | F (%) |
|--------------------------------------------|--------------------|----------|-------------|--------------|-------------|-------|
| Rausch-Derra and Rhodes (2016)             | D1, 1151           | D1, 1.42 | D1, 8.60    | NA           | NA          | NA    |
|                                             | D2, 2730           | D2, 1.83 | D2, 8.45    | D3, 5.05*    |             |       |
|                                             | D3, 2510*          | D3, 1.17*|             |              |             |       |
| De Vito et al. (2017)                      | 7086.9             | NA       | 2.18        | 739.48       | 1258.26     | NA    |
| Nagahisa and Okumura (2017)                | D1, 760            | D1, 0.4  | 4.2         | 348          | NA          | D1, 62|
|                                             | D2, 3600           | D2, 0.58 |             |              |            | D2, 90|
|                                             | D3, 14000          | D3, 0.67 |             |              |            | D3, 110|
| Heit et al. (2018)                         | 5000               | 1        | 4.6         | NA           | NA          | NA    |
| Knych et al. (2018)                        | 31.1               | 1.5      | 5.86        | NA           | NA          | NA    |
| Cox et al. (2020)                          | 106                | 0.5      | NA          | NA           | NA          | NA    |
| Łebkowska-Wieruszewska, Barsotti, et al. (2017) | Fasted, 1598      | Fasted, 1.0 | 5.68        | 460          | 2480        | Fasted, 111.9 | 66.19|
|                                             | Fed, 614           | Fed, 3.0 |             |              |             |       |
| Rausch-Derra, Rhodes, et al. (2016)        | D1, 3520–9210 (T)  | D1, 1.0–2.0 (T) | D1, 1.95–5.42 (T) | 1.64–9.04 (T) | NA          | NA    |
|                                             | 2610–6150 (S)      | 1.0 (S)  | D3, 2.23–7.76 (T) |             |              |       |
|                                             | D3, 94,800–114,000 | D3, 1.0–2.0 (T) | 4.03–5.19 (S) |             |              |       |
|                                             | (T) 46,000–91,900 (S) | 1.0 (S)  |             |              |              |       |
| Łebkowska-Wieruszewska, De Vito, et al. (2017) | 625               | 1.33     | 5.48        | 173.2        | 918.5       | 39.62 |

Abbreviations: Cmax/C0, peak plasma concentration; Tmax, time of peak concentration; t1/2kel, terminal half-life; Cl, plasma clearance; Vss, volume of distribution at the steady state; F, oral bioavailability. NA, not assessed. *, average between sexes. T, tablet; S, suspension. D1, lower dosage; D2, intermediate dosage; D3, higher dosage (for the dose details please refer to Table 2).
A short note reported the pharmacokinetics of grapiprant in Mdr1-deficient collies (Heit et al., 2018). Eight adult collie dogs homozygous for the Mdr1 mutation were treated with approximately, but no less than, 2 mg/kg grapiprant orally once daily for 28 days after an overnight fast. Grapiprant was readily absorbed with a **C**\textsubscript{max} of approximately 5000 ng/ml occurring at a median **T**\textsubscript{max} of 1 h. Although no difference was seen in **t**\textsubscript{1/2} (mean 4.6 h), the **C**\textsubscript{max} and **AUC** (16,000 ng *h*/*ml) were approximately fourfold and sixfold greater, respectively, than those reported in normal Beagles. It was concluded that Mdr1-deficient dogs are expected to have higher **AUC** and **C**\textsubscript{max} values compared to normal dogs treated with the same dose.

The variability in plasma concentrations and in some PK parameters found in the above-mentioned studies might be due to the small animal sample size used. A remarkable result is that oral absorption of grapiprant is decreased by feeding (Łebkowska-Wieruszewska, Barsotti, et al., 2017), this finding is not in line with the report issued by the pharmaceutical company (Anonymous, 2016a, 2016b). However, the instruction sheet of the drug (Anonymous, 2016b) does not recommend administration in the fed state. Indeed, it has been reported that the time range in which grapiprant plasma concentration is above the minimal effective concentration is similar in fasted and fed dogs (Łebkowska-Wieruszewska, Barsotti, et al., 2017) without potential clinical implications. The same can be said for the plasma differences reported in Mdr1-deficient vs. normal dogs. Although the differences in **AUC** values are significant, no adverse effect has been shown in Mdr1 dogs with 6 times higher grapiprant plasma concentrations (Heit et al., 2018).

### 4.2 | Cats

The pharmacokinetics of grapiprant after 2 mg/kg administration via PO and IV (ethanol solution) routes in cats were assessed (Łebkowska-Wieruszewska, De Vito, et al., 2017). Six healthy adult cats were used according to a 2 × 2, randomized cross-over study design. Wide variability in plasma concentration of grapiprant was found after oral administration. Generally, oral absorption was rapid (mean **T**\textsubscript{max} 1.33 h, range 1–2 h) reaching **C**\textsubscript{max} in the range 490–750 ng/ml (median 625 ng/ml). The median **t**\textsubscript{1/2} value (4.40 h) was similar to that found after IV administration. The PO bioavailability was 39.6%. The extraction ratio (Toutain & Bousquet-Méhou, 2004) values in cats were in the range 1.5%–3.7%. These values are considered low and suggest that the contribution of the liver and kidney in the clearance of grapiprant might be limited.

The safety and toxicokinetic profiles associated with daily oral administration of grapiprant were evaluated (Rausch-Derra & Rhodes, 2016). Cats (both gender) were randomly assigned (3 × group) to receive a placebo capsule or grapiprant at 3, 9 or 15 mg/kg, administered PO once daily for 28 days. Very broad variation was found in the pharmacokinetic parameters after the last grapiprant dose. **C**\textsubscript{max} ranged from 683 to 4950 ng/ml with **T**\textsubscript{max} within 1–4 h. Half-lives ranged from 2 to 14 h. The comparison between the **AUC** after the first dose and that at the 27th indicated that no drug accumulation was likely. No apparent differences were reported in the pharmacokinetic parameters between sexes.

### 4.3 | Horses

The drug concentrations and the pharmacokinetics of grapiprant in exercised Thoroughbred horses administered with a 2 mg/kg oral dose of grapiprant were described (Knych et al., 2018).

The **C**\textsubscript{max}, **T**\textsubscript{max} and **t**\textsubscript{1/2} were 31.9 ± 13.9 ng/ml, 1.5 ± 0.5 h and 5.86 ± 2.46 h, respectively. An oral dose of 2 mg/kg appeared not to achieve the MEC reported for dogs (Nagahisa & Okumura, 2017).

A recent study determined if the approved dose of grapiprant in dogs would produce measurable concentrations in urine and plasma of horses (Cox et al., 2020). Six mares were administered one dose of 2 mg/kg grapiprant via nasogastric tube. Grapiprant plasma concentrations ranged from 71 to 149 ng/ml with the mean peak concentration (106 ng/ml) occurring at 30 minutes. This study also reported that oral administration of grapiprant (2 mg/kg) in horses did not achieve the MEC reported for dogs (Nagahisa & Okumura, 2017).

### 4.4 | Rabbits

The pharmacokinetics of grapiprant after 2 mg/kg IV administration were described (De Vito et al., 2017). Grapiprant plasma concentrations were detectable up to the 10-h time point (concentration range 17–7495 ng/ml). Grapiprant was eliminated quite rapidly with a **t**\textsubscript{1/2} value of 2.18 h. Clearance was 739.48 ml/h/kg with a low extraction ratio (range 7.7%–8.9%), and volume of distribution was large (2434.4 ml/kg).

### 5 | PHARMACODYNAMICS

Grapiprant’s mechanism of action targets the EP4 receptor (Figure 2). It does not inhibit the production of other prostanoids and does not interfere with the maintenance of numerous normal homeostatic functions, preventing the classic adverse effects associated with NSAIDs (Giorgi, 2015; Kirkby Shaw et al., 2016).

EP4, along with EP1, EP2, EP3, is one of the target receptors for PGE2 (Woodward et al., 2011), is the most abundant PG in synovia and is a key mediator of inflammation and pain (Yokoyama et al., 2013). The EP4 receptor has been shown to regulate inflammatory nociception at the peripheral and CNS level. Particularly in inflammatory pain, a number of inflammatory mediators in the periphery such as PGs, nerve growth factor and bradykinin activate and/or sensitize neurons (Basbaum et al., 2009; Mizumura et al., 2009). PGE2 is a typical inflammatory mediator released after induction of COX-2 in injured tissue and cells, mostly immune cells such as...
mast cells, basophils or macrophages, which accumulate in the area of injury. PGE2 binds to EP receptors with subsequent activation of intracellular signalling pathways resulting in an increase in intracellular cAMP and thus activation of protein kinases. The latter leads to phosphorylation of a number of target proteins including TRPV1 channels, voltage-gated Na+ or T-type calcium channels which contribute to sensitization mechanisms in the peripheral nervous system (Kawabata, 2011). This sensitization also occurs in the CNS by gene regulation in the pre- and post-synaptic neurons (Kuner, 2010). COX-2 is constitutively expressed in neuronal and glial cells of the CNS and upregulated after ongoing nociceptive stimulation associated with augmented PG synthesis which leads to increased neurotransmitter release (Ferreira & Lorenzetti, 1996; Nishihara et al., 1995), enhanced calcium concentrations and activation of a number of pain-related genes (Figure 3). The consequence of peripheral and central sensitization is an increased sensitivity towards nociceptive stimuli (hyperalgesia) or a nociceptive response to non-noxious stimulation (allodynia).

EP4 plays a crucial role in the development of acute and chronic pain and in inflammation and is therefore one of the most important executors of PGE2 effects in these processes, indicating that this receptor might also be a good target for the development of new anti-inflammatory and analgesic drugs. Peripheral PGE2 prolongs the sensitization of nociceptive dorsal root ganglion neurons possibly by facilitating the synthesis and anterograde axonal trafficking of EP4 receptors (Kawahara et al., 2015; Lin et al., 2006; Schiuffmann et al., 2014; St-Jacques & Ma, 2014).

The canine EP4 receptor has approximately 90% homology to the human receptor (Castleberry et al., 2001), and it is a Gsα- (that stimulates the cAMP-dependent pathway by activating adenylyl cyclase) and Giα- (inhibits the cAMP-dependent pathway by inhibiting adenylyl cyclase) coupled protein (Yokoyama et al., 2013). EP4 signalling plays a variety of roles through stimulating adenylyl cyclase leading to elevated levels of intracellular cAMP (Yokoyama et al., 2013). The EP4 receptor has been showed to be specifically involved in the pain and inflammation associated with experimentally induced arthritis in rodents (Boyd et al., 2011; Chen et al., 2010; Clark et al., 2008; Kabashima et al., 2007; Lin et al., 2006; McCoy et al., 2002; Nakao et al., 2007; Southall & Vasko, 2001; St-Jacques & Ma, 2013).

Grapiprant binds to human and rat EP4 receptors with high affinity (Nakao et al., 2007) and it has been found to have a similar potency in humans (IC50 14 ± 3.9 nM; Ki 13 ± 4 nM), rats (IC50 27 ± 1.3 nM; Ki 20 ± 1 nM) (Nakao et al., 2007) and in dogs (Nagahisa & Okumura, 2017). Grapiprant was found to displace [3H]-PGE2 (1 nM) binding to dog recombinant EP4 receptor in a concentration-dependent manner with an IC50 value of 35 ± 3.9 nM and with a Ki value of 24 ± 2.7 nM (Nagahisa & Okumura, 2017).

5.1 | Dogs

The oral dose predicted to be efficacious in dogs was computed based on the comparison between the affinity of grapiprant to dog, rat and human EP4 receptors. It resulted in a range of 1.3 and 1.7 mg/
kg once a day (Nagahisa & Okumura, 2017) while the approved clinical dose was set at 2 mg/kg once a day (Rausch-Derra, Huebner, et al., 2016). The calculated MEC range and efficacious AUC\textsubscript{0-24} were 114–164 ng/ml and 3936 ng h/ml, respectively (Nagahisa & Okumura, 2017).

The efficacy and safety of grapiprant in dogs with natural OA were assessed (Rausch-Derra, Huebner, et al., 2016). Two hundred and eighty-five client-owned dogs with OA were enrolled and treated with grapiprant or placebo with 262 cases (N = 131 in each group) available for the effectiveness analysis. In this prospective, randomized, masked, placebo-controlled study, dogs were treated daily with grapiprant (2 mg/kg) PO or placebo. Owners completed an evaluation using the Canine Brief Pain Inventory (CBPI) on days 0, 7, 14, 21 and 28. Success was defined as improvement in the CBPI. Veterinary assessments were made on screening and days 14 and 28. Safety was evaluated by physical examination, evaluation of clinical pathology results and owner observations. Grapiprant treatment significantly improved pain compared to placebo on day 28 (48.1 and 31.3% treatment successes, respectively; \( p = 0.0315 \)). The pain interference score and pain severity score improved in the grapiprant group compared to placebo (\( p = 0.0029 \) and \( p = 0.0022 \), respectively). Veterinary assessments were significantly better in the grapiprant-treated dogs (\( p = 0.0086 \)).

A randomized, two-sequence, assessor-blinded study involving two separate experiments measured the potency and persistence of acute pain control over 24 h resulting from a single oral dose of either firocoxib (5.7–8.5 mg/kg) or grapiprant (1.5–2.9 mg/kg) in an acute canine arthritis urate crystal model in 18 Beagle dogs (de Salazar Alcalá et al., 2019). The analgesic efficacy of each treatment was assessed on the basis of the vertical force (VF) applied by each dog’s hind limb, measured with a force plate and on visual lameness (VL) scores (from 0 to 5) calculated for each dog, on each experiment and at each time point. In both the experiments, firocoxib was superior to grapiprant. Grapiprant was shown to produce an effect not statistically different from the control.

The ability of a proprietary antagonist of the EP\textsubscript{4} receptor (4 mg/kg), grapiprant (2 mg/kg) and carprofen (4.4 mg/kg) to attenuate lameness attributable to urate-induced synovitis was investigated in five dogs (Budsberg et al., 2019). Measurements of vertical ground reaction forces and clinical lameness scores were used to assess the analgesic activities of the different compounds. Carprofen was the most effective treatment for attenuating lameness induced by injection of sodium urate, and grapiprant was the least effective treatment.

Grapiprant is a newly introduced drug, and so reports of testing under laboratory and field conditions have been limited to studies that are required for regulatory approvals (Rausch-Derra, Huebner, et al., 2016). Surprisingly two experimental (Budsberg et al., 2019; de Salazar Alcalá et al., 2019) studies show that grapiprant, a drug with presumptive advantages, has less efficacy than established
treatments. It should be noted that the experimental animal model used (intra-articular injection of sodium urate in the stifle joints of dogs) produces acute pain while grapiprant is approved for chronic pain. It is noteworthy that the same experimental model (adjuvant-induced arthritis) was used in rats to demonstrate the efficacy of grapiprant (Anonymous, 2016a). Several studies have correlated the pain relief produced with this model with those reported in clinical trials attributable to OA in dogs (Borer et al., 2017; Cross et al., 1997; Doig et al., 2000). Unfortunately, only a single clinical trial has been carried out to evaluate the real clinical efficacy of this active ingredient (Rausch-Derra, Huebner, et al., 2016). Although results in general are encouraging, the efficacy compared to the placebo had a p value of 0.044, which is barely significant, and the efficacy response was only 41%–46%. Additional trials are warranted to confirm its efficacy.

5.2 | Rabbits

The thermal antinociceptive effect of grapiprant in the induced inflammatory pain model in the rabbit after a single IV injection of 2 mg/kg was evaluated and compared with that generated by 0.5 mg/kg meloxicam injected subcutaneously (De Vito et al., 2017). An infrared thermal stimuli was applied to the plantar surface of the rabbits’ hindlimbs to evaluate the thermal withdrawal latency (TWL). The thermal antinociceptive effect was expressed as maximum possible response. The grapiprant-treated animals showed a significant increase in TWL from 1 h and up to 10 h after drug administration compared to the control and TWL was higher than meloxicam in the range 1–2 h and at 10 h. The difference in efficacy in the initial hours was supposed to be due to the different routes of administration of the two drugs. The increased efficacy shown at 10 h was speculated to be due to the different doses of drugs administered, to a wider counter-clockwise hysteresis loop or to a potential active metabolite (never detected) of grapiprant that might have prolonged the treatment effect. Also the different mechanisms of action of the two drugs might have played a role in this effect. The antinociceptive effect of grapiprant and meloxicam was not found to be statistically different in the time range 4–8 h.

6 | SAFETY PROFILE

6.1 | Dogs

None of the studies administering a single oral dose in dogs (even larger that the clinical one) reported any visible side effect (Łebkowska-Wieruszewska, Barsotti, et al., 2017; Nagahisa & Okumura, 2017).

The safety of long-term, daily oral administration of grapiprant was tested (Rausch-Derra et al., 2015). Thirty-six dogs were randomly assigned to four groups (8 dogs/group) that received grapiprant via oral gavage at 0, 1, 6 or 50 mg/kg, once a day for 9 months. All dogs received daily ophthalmologic, ECG, and laboratory evaluations before treatment began (baseline) and periodically afterwards. Dogs were euthanized at the end of the study for necropsy and histologic evaluation. All dogs remained clinically normal during treatment, with no apparent changes in appetite or demeanour. Emesis and soft or mucoid faeces that occasionally contained blood were observed in all groups, although these findings were more common in dogs that received grapiprant. In general, clinicopathologic findings remained within baseline ranges. Drug-related changes in serum total protein and albumin concentrations were detected, but differences were small and resolved during recovery. No drug-related gross or microscopic pathological changes were detected in tissue samples except mild mucosal regeneration in the ileum of one dog in the 50 mg/kg group. These findings suggested that long-term administration of grapiprant is safe in dogs. It might be suggested that if any other NSAID was administered once daily for 9 months at 25 times its clinical dose, the consequences would have been more serious than those reported for grapiprant.

To the best of Authors’ knowledge, no study comparing the adverse effects of grapiprant and any other NSAID is available. However, the pharmaceutical company reports that a dog group (n = 94) treated with 2 mg/kg once daily dose had similar incidence rates for adverse events (diarrhoea, vomiting and inappetence) to the placebo group (n = 88) (Anonymous, 2016a).

When an oral dose of 2 mg/kg was administered daily for 28 days to normal Beagles and Mdr1-deficient dogs, despite grapiprant exposure being greater in these latter animals, no differences in general health, clinical sign or body weight were found (Heit et al., 2018).

6.2 | Cats

A single oral dose of grapiprant at 2 mg/kg (IV and PO) did not produce visible side effects in cats (Łebkowska-Wieruszewska, De Vito, et al., 2017).

The safety profile was evaluated after daily PO administration of 3, 9 or 15 mg/kg over a period of 4 weeks (Rausch-Derra & Rhodes, 2016). Grapiprant was well tolerated, and no adverse effects were detected at doses ≤15 mg/kg. No significant effects on body weight, food consumption, clinicopathologic variables, or gross or histologic necropsy findings were noted.

6.3 | Other animal species

Rabbits after single IV (0.5 mg/kg) and PO (2 mg/kg) dose and horses after single PO dose (2 mg/kg) did not report any significant adverse effects (Cox et al., 2020; De Vito et al., 2017; Knych et al., 2018).

7 | CONCLUSION

A number of studies have been carried out to assess diverse analytical methods for grapiprant quantification, its pharmacokinetics,
pharmacodynamics and safety especially in the canine species. The pharmacokinetic profile seems well characterised in dogs. Although some data are conflicting (oral bioavailability fed vs. fasted), the differences in plasma concentrations might not generate appreciable variation in clinical efficacy. In terms of efficacy, grapiprant is barely better than placebo and inferior to other traditional NSAIDs. It may be an alternative to traditional NSAIDs because of its alternative mode of action, however, further clinical studies are warranted to clarify this point.

ACKNOWLEDGEMENT
Authors would like to express their gratitude to Dr H Owen (University of Queensland, Australia) for her English editing of the manuscript.

CONFLICT OF INTEREST
Authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS
MG and IS conceived of the presented idea. Both authors read and discussed the literature and contributed to the final manuscript.

DATA AVAILABILITY STATEMENT
Please contact the author for any requests for access to the data.

ORCID
Irene Sartini https://orcid.org/0000-0002-0538-4563
Maria Giorgi https://orcid.org/0000-0003-3657-4703

REFERENCES
Anonymous (2016a). NADA 141-455 GALLIPRANT. https://animaldrugsatfda.fda.gov/ada/fda/app/search/public/document/downloadFile/941
Anonymous (2016b). Galignprant prescribing information. Aratana Therapeutics. https://files.briefvet/2018-07/Galliprant%20Prescribing%20Information_Elanco.pdf
Baralla, E., Vito, V. D., Varoni, M. V., Giorgi, M., & Demontis, M. (2018). Novel LC-MS/MS method for CJ-023423 (grapiprant) determination in rabbit plasma. American Journal of Animal and Veterinary Sciences, 13, 45–50. https://doi.org/10.3844/ajavsp.2018.45.50
Basbaum, A. I., Bautista, D. M., Scherrer, G., & Julius, D. (2009). Cellular and molecular mechanisms of pain. Cell, 139, 267–284. https://doi.org/10.1016/j.cell.2009.09.028
Borer, L. R., Seewald, W., Peel, J. E., & King, J. N. (2017). Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs. Journal of Veterinary Pharmacology and Therapeutics, 40, 148–157. https://doi.org/10.1111/jvp.12348
Boyd, M. J., Berthelette, C., Chiasson, J. F., Clark, P., Colucci, J., Denis, D., Han, Y., Lévesque, J. F., Mathieu, M. C., Stocco, R., Therien, A., Rowland, S., Wrona, M., & Xu, D. (2011). A novel series of potent and selective EP4 receptor ligands: facile modulation of agonism and antagonism. Bioorganic & Medicinal Chemistry Letters, 21, 484–487. https://doi.org/10.1016/j.bmcl.2010.10.106
Budsgen, S. C., Kleine, S. A., Norton, M. M., & Sandberg, G. S. (2019). Comparison of two inhibitors of E-type prostanooid receptor four and carprofen in dogs with experimentally induced acute synovitis.
Johnston, S. A., McLaughlin, R. M., & Budsberg, S. C. (2008). Nonsurgical management of osteoarthritis in dogs. *Veterinary Clinics of North America: Small Animal Practice, 38*, 1449–1470. https://doi.org/10.1016/j.cv.svn.2008.08.001

Kabashima, K., Nagamachi, M., Honda, T., Nishigori, C., Miyachi, Y., Tokura, Y., & Narumiya, S. (2007). Prostaglandin E2 is required for ultraviolet-induced skin inflammation via EP2 and EP4 receptors. *Laboratory Investigation, 87*, 49–55. https://doi.org/10.1038/labinvest.3700491

Kawabata, A. (2011). Prostaglandin E2 and pain—an update. *Biological and Pharmaceutical Bulletin, 34*, 1170–1173. https://doi.org/10.1248/bpb.34.1170

Kawahara, K., Hohjo, H., Inazumi, T., Tsuchiya, S., & Sugimoto, Y. (2015). Prostaglandin E2-induced inflammation: relevance of prostaglandin E receptors. *Biochimica Et Biophysica Acta, 1851*, 414–421. https://doi.org/10.1016/j.bbapal.2014.07.008

Kim, T. W., & Giorgi, M. (2013). A brief overview of the coxib drugs in the veterinary field. *American Journal of Animal and Veterinary Science, 8*, 89–97. https://doi.org/10.3844/ajavsp.2013.89.97

Kirkby Shaw, K., Rausch-Derra, L. C., & Rhodes, L. (2016). Grapiprant: An EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. *Veterinary Medicine and Science, 2*, 3–9.

Knych, H. K., Seminoff, K., & McKemie, D. S. (2018). Detection of grapiprant following oral administration to exercised Thoroughbred horses. *Drug Test Analysis, 10*, 1237–1243.

Kuner, R. (2010). Central mechanisms of pathological pain. *Nature Medicine, 16*, 1258–1266. https://doi.org/10.1038/nm.2231

Łębkowska-Wieruszewska, B., Barsotti, G., Lisowski, A., Gazzano, A., Owen, H., & Giorgi, M. (2017). Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E2 receptor antagonist, after oral administration in fasted and fed dogs. *New Zealand Veterinary Journal, 65(1)*, 19–23.

Łębkowska-Wieruszewska, B., De Vito, V., Owen, H., Poopholat, A., & Giorgi, M. (2017). Pharmacokinetics of grapiprant, a selective EP4 prostaglandin PGE2 receptor antagonist, after 2 mg/kg oral and iv. administrations in cats. *Journal of Veterinary Pharmacology and Therapeutics, 40(6)*, e11–e15.

Lin, C. R., Amaya, F., Barrett, L., Wang, H., Takada, J., Samad, T. A., & Clifford, J. W. (2006). Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. *Journal of Pharmacology and Experimental Therapy, 319*, 1096–1103.

McCoy, J. M., Wicks, J. R., & Audoly, L. P. (2002). The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. *The Journal of Clinical Investigation, 110*, 651–658. https://doi.org/10.1172/JCI215528

McLaughlin, R. (2000). Management of chronic osteoarthritic pain. *Veterinary Clinics of North America: Small Animal Practice, 30*, 933–949. https://doi.org/10.1016/S0195-5616(08)70016-0

Mizumura, K., Sugita, T., Katanosaka, K., Banik, R. K., & Kozaki, Y. (2009). Excitation and sensitization of nociceptors by bradykinin: what do we know? *Experimental Brain Research, 196*, 53–65. https://doi.org/10.1007/s00221-009-1814-5

Nagahisa, A., & Okumura, T. (2017). Pharmacology of grapiprant, a novel EP4 antagonist: Receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs. *Journal of Veterinary Pharmacology and Experimental Therapeutics, 40*, 285–292. https://doi.org/10.1111/jvet.12349

Nakao, K., Murase, A., Ohshiro, H., Okumura, T., Taniguchi, K., Murata, Y., Masuda, M., Kato, T., Okumura, Y., & Takada, J. (2007). CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. *Journal of Pharmacology and Experimental Therapeutics, 322*, 868–869.

Nishihara, I., Minami, T., Watanabe, Y., Ito, S., & Hayaishi, O. (1995). Prostaglandin E2 stimulates glutamate release from synaptosomes of rat spinal cord. *Neuroscience Letters, 196*, 57–60. https://doi.org/10.1016/0304-3940(95)11839-O

Rausch-Derra, L. C., Huebner, M., & Rhodes, L. (2015). Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs. *American Journal of Veterinary Research, 76*, 853–859. https://doi.org/10.2460/ajvr.76.10.853

Rausch-Derra, L. C., Huebner, M., Wofford, J., & Rhodes, L. A. (2016). A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis. *Journal of Veterinary Internal Medicine, 30*, 756–763.

Rausch-Derra, L. C., & Rhodes, L. (2016). Safety and toxicokinetic profiles associated with daily oral administration of grapiprant, a selective antagonist of the prostaglandin E2 EP4 receptor, to cats. *American Journal of Veterinary Research, 77*, 688–692.

Rausch-Derra, L. C., Rhodes, L., Freshwater, L., & Hawks, R. (2016). Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs. *Journal of Veterinary Pharmacology and Therapeutics, 39*, 566–571. https://doi.org/10.1111/j.vpt.12306

Rychel, J. K. (2010). Diagnosis and treatment of osteoarthritis. *Top Companion Animal Medicine, 25*, 20–25. https://doi.org/10.1053/j.tcam.2009.10.005

Schliffmann, S., Weigert, A., Mannich, J., Eberle, M., Birod, K., Häusser, A., Ferreiros, N., Schreiber, Y., Kunkel, H., Grez, M., Weichand, B., Brüne, B., Pfeilschifter, W., Nüsing, R., Niederberger, E., Grösch, S., Scholich, K., & Geisslinger, G. (2014). PGE2/EP4 signaling in peripheral immune cells promotes development of experimental autoimmune encephalomyelitis. *Biochemical Pharmacology, 87*, 625–635. https://doi.org/10.1016/j.bcp.2013.12.006

Southall, M. D., & Vasko, M. R. (2001). Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced CAMP production and sensitization of sensory neurons. *The Journal of Biological Chemistry, 276*, 16083–16091. https://doi.org/10.1074/jbc.M011408200

St-Jacques, B., & Ma, W. (2013). Prostaglandin E2/EP4 signalling facilitates EP4 receptor externalization in primary sensory neurons in vitro and in vivo. *Pain, 154*, 313–323. https://doi.org/10.1016/j.pain.2012.11.005

St-Jacques, B., & Ma, W. (2014). Peripheral prostaglandin E2 prolongs the sensitization of nociceptive dorsal root ganglion neurons possibly by facilitating the synthesis and anterograde axonal trafficking of EP4 receptors. *Experimental Neurology, 261*, 354–366. https://doi.org/10.1016/j.expneurol.2014.05.028

Toutain, P. L., & Bousquet-Mélou, A. (2004). Plasma clearance. *Journal of Veterinary Pharmacology and Therapeutics, 27*, 415–425. https://doi.org/10.1111/j.1365-2885.2004.00605.x

Woodward, D. F., Jones, R. L., & Narumiya, S. (2011). International Union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. *Prostaglandins, Leukotrienes and Essential Fatty Acids, 85*, 1010–1052. https://doi.org/10.1016/j.plefa.2011.04.021

Yokoyama, U., Iwatsubo, K., Umemura, M., Fujita, T., & Ishikawa, Y. (2013). The Prostanoid EP4 receptor and its signaling pathway. *Prostaglandin and Related Substances Reviews, 65*, 1010–1052. https://doi.org/10.1124/pr.112.007195

**How to cite this article:** Sartini, I., & Giorgi, M. (2021). Grapiprant: A snapshot of the current knowledge. *Journal of Veterinary Pharmacology and Therapeutics, 00*, 1–10. https://doi.org/10.1111/jvp.12983